JNJ

Novavax’s stock rises as its Covid-19 vaccine outpaces J&J

Johnson & Johnson (JNJ) Covid-19 Vaccine Shot provides strong protection under test

Johnson & Johnson JNJ profit, fourth quarter 2020

It was a dark morning in the Covid-19 fight. The market is looking for hope at Johnson & Johnson.

J&J can share findings from the Phase 3 vaccine trial this week

The ‘last cry’ of technology? If hedge funds are any indication, it could be a great week for Apple, Amazon and other prominent megacaps

Johnson & Johnson targets 100 million doses of vaccine by spring. The stock market is counting on that.

J&J Hits Vaccine Production Snags, New York Times Reports

The Johnson & Johnson Covid-19 vaccine could change the course of the pandemic. Investors will soon know if it works.

Covid-19 vaccines to work on South African coronavirus strain

Three more coronavirus vaccines are expected by early 2021